Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
about
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyRisk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple SclerosisMitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosisCardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) studyAnthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature ReviewCan we prevent or treat multiple sclerosis by individualised vitamin D supply?Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?Current disease-modifying treatment of multiple sclerosis.Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease.The transition from first-line to second-line therapy in multiple sclerosis.Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients.Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis.Drugs approved for the treatment of multiple sclerosis: review of their safety profile.Redox-triggered mitoxantrone prodrug micelles for overcoming multidrug-resistant breast cancer.[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress.Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
P2860
Q22241650-C7312422-45C1-4FDB-9A9D-79F48E55B7FAQ28087414-2DD88856-CF1D-4FB7-A9CC-C55EA468EC47Q28480940-27C26285-0653-42AD-9B73-4928945083D2Q33899881-24FB2974-4819-4E58-ACE9-4B19BD8ECE5BQ34630494-B46F3529-9F10-4341-AE7E-7288A3131900Q34810005-57EBB377-029E-472F-BD99-C7A62837CACEQ35888110-8C290BCD-12EB-4B52-BD4B-169E31392E37Q36588696-7A311116-CD94-4A40-A366-C91A1385EF31Q36648907-2C1031F6-4661-439B-AB4D-BE42452436D1Q37855719-424F6288-D6DC-4737-93ED-0CB100FF2203Q40355162-E2915FDC-8F1F-4F84-B109-A67EBFD41A4BQ40628996-03FF5AB1-7FFA-4E12-B6E7-EF06F7735468Q41014662-9C8D4C38-FF54-4CA3-B1B3-66F1B9DCE63CQ41998267-930FC8D4-2D68-4213-9672-5BEB28CEF705Q42920232-7FDB2352-2673-4907-BE4B-8E7A73F2C712Q47868767-40B0D3B8-F4A2-4ACF-BFE7-9672BDD9D41AQ50852004-F760F12C-DEFF-46E3-ADF7-48CB9D4EA969Q52855510-B111E0FB-B849-4BE1-8539-5132C405E822Q54959206-BAF92F99-E4CA-49EF-ACD3-4B96CA0A16DAQ58573155-9959E14D-216C-4BA6-AB63-E8C25F920DAC
P2860
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
description
im Februar 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 February 2007
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2007
@uk
name
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
@en
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
@nl
type
label
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
@en
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
@nl
prefLabel
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
@en
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
@nl
P2093
P2860
P356
P1476
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
@en
P2093
P2860
P304
P356
10.1136/JNNP.2006.091033
P407
P577
2007-02-01T00:00:00Z